

**ScinoPharm Taiwan, Ltd.**  
**2026 Annual General Shareholders' Meeting Minutes**  
**(Translation)**

Time and Date: 10:00a.m., Wednesday May 27, 2026

Place: ScinoPharm Taiwan, Ltd. (Corporate location)

1 Nan-Ke 8<sup>th</sup> Road, Southern Taiwan Science Park, Shan-Hua, Tainan, Taiwan

Convene Format: Physical Shareholders' Meeting

Attendants: All shareholders and their proxy holders, representing 588,912,269 shares (among them 512,221,591 shares voted via electronic transmission), or 74.47% of the total 790,739,222 outstanding shares.

Chairperson: Chih-Hsien Lo

Recorder: Yung-Chih Tsai

Directors Present: Chairman Chih-Hsien Lo 、

Lewis Lee (independent director- Chairman of the Audit committee)

Tsung-Pin Wu 、 Jia-Horng Guo 、 Chyun-Yu Yang 、 Fu-Jung Lai 、

Ming-Chuan Hsieh 、 Ya-Po Yang 、 Chiou-Ru Shih 、 Ling Ming Sun 、

Wen-Chang Chang (independent director) 、 Li-Tzong Chen (independent

director) 、 Lai-Shou Su (independent director)

13 seats of Directors attended the Meeting and presented Directors are over one-half of 17 seats Directors.

Attendees: Li-An Lu (President & CEO of ScinoPharm Taiwan, Ltd.)

Hui-Yu Hsu (CPA), Blake Wu (Attorney)

The aggregate shareholding of the shareholders presents in person or by proxy constituted a quorum. The chairman called the meeting to order.

**A. Chairman's Address (omitted)**

**B. Report Items**

(1) 2025 Business Report.

Explanation: The business report for 2025 is attached as Appendix 1.

(2) Audit Committee's Review Report on 2025 Financial Results.

Explanation: The Audit Committee Review Report is attached as Appendix 2.

(3) 2025 Remuneration for Employees and Directors.

Explanation:

- a. The remuneration distribution for employees and directors on 2025 is calculated according to Article 40 of the Articles of Incorporation: "Should the Company earn surpluses within the current term, at least two percent of surpluses should be set aside for employee compensation (compensation for grassroots employees shall be no less than one percent), and no more than two percent of surpluses should be set aside for directors' compensation...".
- b. According to the Articles of Incorporation, the employees' compensation for 2025 was NT\$14,732,544, making up 8.97% of the year's profit. The company's grassroots employees are "non-managerial employees whose salaries are below the grassroots employees' salary level as defined in the Regulations on Additional Deduction of Expenses for Salary Increase of Small and Medium-sized Enterprises (NT\$63,000 monthly average regular salary in 2025)". The number of such employees is 299, and the total amount of compensation distributed to

them is NT\$4,626,911. Directors' compensation was NT\$2,191,211, making up 1.33% of the year's profits; all compensation was distributed in cash. The aforementioned amounts differed from accrued amounts by 0 for both employees' remuneration and directors' remuneration.

### C. Ratification Items

(1) Ratification of 2025 Business Report and Financial Statements. (Proposed by the Board)

Explanation:

- a. The Parent and Consolidated Financial Statements for 2025 of the Company as adopted by the March 4, 2026 meeting of the Board of Directors and duly certified by Fang-Ting Yeh, Certified Public Accountant and Hui-Yu Hsu, Certified Public Accountant from PricewaterhouseCoopers Taiwan were duly submitted in conjunction with the Business Report to the Audit Committee for inspection. This inspection was completed with the Auditors Committee's Review Reports duly issued.
- b. Please see Appendix 1 and Appendices 3~4 for the Business Report, Auditors' Reports, parent and consolidated financial statements.

Voting Result –

Shares represented at the time of voting: 583,248,980

Voting Results*		% of the total represented share present
Votes in favor:	579,358,510 votes (508,337,893) votes	99.33%
Votes against:	899,398 votes (899,398 votes)	0.16%
Abstained votes/ No vote:	2,991,072 votes (2,984,300 votes)	0.51%
Votes invalid	0 votes	0%

\*including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

(2) Ratification of the Proposed Distribution of 2025 Earnings. (Proposed by the Board)

Explanation:

- a. The 2025 Earning Distribution Proposal is attached as Appendix 5.
- b. The Company's distributable earnings for 2025 are NT\$456,081,983. Proposed cash dividend is NT\$229,314,375; the cash dividend to be distributed is NT\$0.29 per share. Upon the approval of the General Shareholders' Meeting, it is proposed that the Board of Directors be authorized to resolve the ex-dividend date, payment date, and adjust the dividends to be distributed to each share based on the number of actual shares outstanding on the record date for distribution.
- c. Cash dividends paid to each individual shareholder will be rounded down to the nearest dollar. Fractional shares with a value less than one dollar are accumulated and reported as the Company's other income.

Voting Result –

Shares represented at the time of voting: 583,248,980

Voting Results*		% of the total represented share present
Votes in favor:	579,391,313 votes (508,370,696 votes)	99.34%
Votes against:	903,206 votes (903,206 votes)	0.15%
Abstained votes/ No vote:	2,954,461 votes (2,947,689 votes)	0.51%
Votes invalid	0 votes	0%

\*including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

**D. Discuss Items**

(1) Proposed Amendments to the Articles of Incorporation of the Company.

(Proposed by the Board)

Explanation:

- a. In accordance with the Financial Supervisory Commission's "Corporate Governance 3.0 - Sustainable Development Blueprint" and the explanation letter of TWSE, No.1120014763 on Aug. 23, 2023 revision of article 4 of the "Taiwan Stock Exchange Corporation Directions for Compliance with the Establishment of Board of Directors by TWSE Listed Companies and the Board's Exercise of Powers": the number of independent directors shall not be less than three. Furthermore, starting in 2027, the number of independent directors of listed companies shall not be less than one-third of the total number of directors. To comply with regulatory requirements and corporate governance practices, the Company is revising the Article of Incorporation of the Company.
- b. Key revision: The number of directors has been adjusted from seventeen to twelve, of whom no fewer than three shall be independent directors, and independent directors shall constitute no less than one-third of the board seats.
- c. Please refer to Appendix 6 of Contrast table for Amendments to the Articles of Incorporation of the Company.

Voting Result –

Shares represented at the time of voting: 583,248,980

Voting Results*		% of the total represented share present
Votes in favor:	578,955,763 votes (507,935,146 votes)	99.26%
Votes against:	1,025,812 votes (1,025,812 votes)	0.18%
Abstained votes/ No vote:	3,267,405 votes (3,260,633 votes)	0.56%
Votes invalid	0 votes	0%

\*including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

(2) Proposed Amendments to the Operational Procedures for Acquisition and Dispose of Assets of the Company. (Proposed by the Board)

Explanation:

- a. According to the decree of The Financial Supervisory Commission on July 24, 2025, No.1140383333, on revision of the "Regulations Governing the Acquisition and Disposal of Assets by Public Companies", adding provisions to relax the public announcement and reporting standards for companies with paid-in capital of NT\$50 billion or more when acquiring or disposing of equipment for business use with non-related parties. Based on the company's paid-in capital and the regulatory announcement and reporting standards, and because the regulations for companies with paid-in capital of NT\$10 billion or more and the FSC's relaxed regulations for companies with paid-in capital of NT\$50 billion do not apply, the content of item 4 of the first paragraph of this article is amended.
- b. Key revision: Based on the company's paid-in capital and regulatory announcement and reporting standards, and because regulations pertaining to companies with paid-in capital of NT\$10 billion or more and the Financial Supervisory Commission's (FSC) recent relaxation to NT\$50 billion do not apply, Section 1, Item 4 of Article 10 of this procedure is revised.
- c. Please refer to Appendix 7 of Contrast table for Amendments to the Operational Procedures for Acquisition and Dispose of Assets of the Company.

Voting Result –

Shares represented at the time of voting: 583,248,980

Voting Results*		% of the total represented share present
Votes in favor:	579,070,918 votes (508,050,301 votes)	99.28%
Votes against:	912,542 votes (912,542 votes)	0.16%
Abstained votes/	3,265,520 votes	0.56%
No vote:	(3,258,748 votes)	
Votes invalid	0 votes	0%

\*including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

(3) Proposed release the Directors (including Independent Directors) and their representatives from non-competition restrictions. (Proposed by the Board)

Explanation:

- a. According to the Article 209 of Company Act, any director acting for himself/herself, or for any other person within the scope of the Company business, should provide the shareholders' meeting with explanations about any important matters of such acts and should acquire the approval of the Shareholders' Meeting.
- b. It is proposed to seek approval In the General Shareholders' Meeting allowing directors (including Independent directors) and their representatives to engage in acts of competition under Article 209 of Company Act, thus be released during their terms from the competition restriction (provided that there's no damage to the interests of the Company).
- c. Titles and job details of directors (including independent directors) and their representatives who will be exempting from non-compete competition prohibition as show in Appendix 8.

Voting Result –

Shares represented at the time of voting: 583,248,980

Voting Results*		% of the total represented share present
Votes in favor:	579,213,179 votes (508,192,562 votes)	99.31%
Votes against:	1,123,821 votes (1,123,821 votes)	0.19%
Abstained votes/	2,911,980 votes	0.50%
No vote:	(2,905,208 votes)	
Votes invalid	0 votes	0%

\*including votes casted electronically (numbers in brackets)

RESOLVED, that the above proposal be and hereby was approved as proposed.

**E. Extemporary motions**

**F. Meeting adjourned: Meeting adjourned at 10:31 AM, May 27<sup>th</sup> 2026**

There's no question to the Company by attending shareholders.

## **Appendix 1**

### **ScinoPharm Taiwan, Ltd.**

#### **Letter to Shareholders**

In 2025, according to forecasts by major international institutions, global economic growth remained moderate, although the pace of expansion slowed. Inflationary pressures in major economies gradually eased, and market expectations pointed to a gradual interest rate easing cycle. Monetary policies sought to balance inflation control with economic stability, while central banks continued to respond prudently to geopolitical uncertainties, energy price volatility, and fiscal pressures. The U.S. economy demonstrated relative resilience, supported by technology investment and consumer spending. China continued to stabilize domestic demand and promote industrial upgrading through policy initiatives, while Europe's recovery remained moderate amid energy cost pressures and regional security concerns. Meanwhile, global supply chain restructuring continued, with enterprises placing greater emphasis on regionalization and supply resilience. Investments in artificial intelligence, advanced manufacturing, and green transformation—driven by policy support and corporate capital expenditures—continued to promote industrial upgrading and cross-border collaboration. Against this complex and uncertain external environment, ScinoPharm Taiwan adhered to a prudent operating philosophy and a long-term strategy focused on high-potential markets. The Company remained committed to strengthening its core pharmaceutical technologies and high-quality manufacturing capabilities, enhancing its product portfolio, and maintaining flexibility in response to evolving market and regulatory conditions. Through continued portfolio optimization and global expansion, ScinoPharm Taiwan laid a solid foundation for sustainable mid- to long-term growth.

In 2025, consolidated revenue reached NT\$3.163 billion, with net income after tax of NT\$137 million and earnings per share of NT\$0.17. As of year-end, paid-in capital totaled NT\$7.907 billion, while shareholders' equity amounted to NT\$10.525 billion, representing 88.76% of total assets of NT\$11.858 billion. The Company maintained a sound and stable financial structure, with long-term funds covering fixed assets by 3.27 times and a current ratio of 7.74 times, reflecting strong liquidity and financial resilience.

#### **Strengthening Three Core Business Pillars**

ScinoPharm Taiwan continued to focus on the development of its three core businesses—proprietary active pharmaceutical ingredients (APIs), proprietary finished dosage forms (formulations), and contract development and manufacturing (CDMO)—while further enhancing its technological competitiveness and market presence. In the proprietary API segment, shipment volumes of key products achieved double-digit growth. Two additional oncology products completed Drug Master File registrations, reinforcing the Company's development pipeline. ScinoPharm Taiwan continued to optimize production capacity and supply chain flexibility to respond effectively to pricing competition, while actively expanding into new markets and customer bases in regions including China, Europe, and South America. These efforts enabled the Company to further integrate into customers' supply chains and maximize the value of its proprietary API portfolio.

In proprietary finished dosage forms, the Company focused on high-value injectable and drug-device combination products, targeting therapeutic areas such as oncology, hematology, metabolic disorders, and central nervous system diseases. As part of its global commercialization strategy, ScinoPharm Taiwan has consistently prioritized the United States as a key market for regulatory filings and commercial deployment, while continuing to expand its injectable product portfolio. In early 2026, the Company successfully obtained U.S. FDA approval for Glatiramer Acetate Injection for the treatment of multiple sclerosis, with two additional products currently under FDA review. In Taiwan, the Company has obtained marketing approval for Bortezomib for multiple myeloma and is actively pursuing National Health Insurance reimbursement. Applications for diabetes treatments remain under review, and multiple additional regulatory submissions are planned to benefit local patients and anchor internationally recognized development capabilities and high-quality medicines in Taiwan. Non-U.S. market expansion has also commenced, with ongoing efforts to advance strategic collaborations across Europe, Asia, and emerging markets.

In the CDMO business, ScinoPharm Taiwan focused on its strengths in peptides, steroids, and cytotoxic products. The business development team actively showcased the Company's technological capabilities through international exhibitions, pursuing collaboration opportunities with innovative pharmaceutical companies. By leveraging its manufacturing capacity and expertise in peptide and cytotoxic products, ScinoPharm Taiwan expanded its contract manufacturing portfolio and diversified its customer base. The Company continued to provide integrated services across APIs and finished dosage forms, strengthening long-term partnerships and enhancing growth momentum.

In response to growing demand in China, subsidiary SciAnda (Changshu) Pharmaceuticals, Ltd. actively expanded its proprietary API customer base and deepened collaboration with local finished dosage form manufacturers. Through multiple GMP compliance inspections, the subsidiary provided strong regulatory support for customer product launches and submitted additional regulatory filings. Beyond serving domestic demand, SciAnda Changshu Pharmaceuticals also targeted international markets and expanded its CDMO business, reinforcing its operational foundation and customer engagement in the region.

### **Brand, Sustainability, and Long-Term Outlook**

The year 2025 marked a milestone in strengthening ScinoPharm Taiwan's brand communication. The Company reaffirmed that its purpose extends beyond manufacturing medicines to safeguarding life and health, formally defining its brand spirit, vision, mission, and core values. This initiative aligned employees around shared goals while clearly communicating the Company's value proposition as it advances toward becoming an internationally recognized pharmaceutical company. ScinoPharm Taiwan also remained committed to sustainable operations. The Company completed its 2024 greenhouse gas inventory covering Scopes 1 to 3, obtained third-party limited assurance in accordance with the GHG Protocol, and was recognized as one of CommonWealth Magazine's "Excellence in Corporate Social Responsibility Award." In addition, we successfully passed the Taiwan Intellectual Property Management System (TIPS) verification in 2025, achieving A-level certification.

Looking ahead, ScinoPharm Taiwan will continue to deepen collaboration with global pharmaceutical partners, enhance international visibility, and expand its presence in small-molecule drugs, peptide therapeutics, and high value-added products. While advancing its global footprint, the Company remains committed to strengthening domestic supply capabilities in Taiwan, responding to government initiatives to enhance pharmaceutical supply resilience, and creating long-term value for shareholders through steady and sustainable growth.

**Appendix 2**

**Audit Committee's Review Report**

The Board of Directors has prepared the Company's 2025 Business Report, Parent and Consolidated Financial Statements, and proposal for allocation of profits. The CPA firm of PricewaterhouseCoopers Taiwan was retained to audit the Company's Financial Statements and has issued an audit report relating to the Financial Statements. The Business Report, Financial Statements, and profit allocation proposal have been reviewed and determined to be correct and accurate by the Audit Committee members of ScinoPharm Taiwan, Ltd. According to Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act, we hereby submit this report.

ScinoPharm Taiwan, Ltd.

Chairman of the Audit Committee: Lewis Lee

March 4, 2026

---

## **Appendix 3**

### INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of ScinoPharm Taiwan, Ltd.

#### ***Opinion***

We have audited the accompanying parent company only balance sheets of ScinoPharm Taiwan, Ltd. (the "Company") as at December 31, 2025 and 2024, and the related parent company only statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the parent company only financial statements, including a summary of material accounting policies.

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2025 and 2024, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

#### ***Basis for opinion***

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the *Auditors' responsibilities for the audit of the parent company only financial statements* section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountants in the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### ***Key audit matters***

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Company's 2025 parent company only financial statements. These matters were addressed in the context of our audit of the parent company only financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

The key audit matters for the Company's 2025 parent company only financial statements are stated as follows:

#### ***Occurrence of sales revenues from API and injection products***

##### Description

Refer to Note 4(26) for accounting policy on revenue recognition and Note 6(17) for accounting items on revenue.

The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient ("API") and injection products. The Company's customers come from Taiwan, Asia, Europe and America. Since the volume and amount of transactions are significant, we

considered the occurrence of sales revenue from API and injection products a key audit matter.

#### How our audit addressed the matter

We performed the following key audit procedures in response to the above key audit matter:

1. We evaluated the internal control system that was designed and implemented by management in reviewing customers' credit, and tested whether the counterparty and the credit valuation documents have been properly approved.
2. We sampled transaction details and supporting documents for consistency from transaction counterparties who have higher turnover growth.
3. We sent confirmation letters for significant year-end accounts receivable, ascertained whether the responses and account records were consistent with customers' data, and evaluated the reasonableness on the difference between the responses and the account records.

### ***Inventory valuation***

#### Description

Refer to Note 4(11) for accounting policies on inventory valuation, Note 5(2) for the uncertainty of accounting estimates and assumptions applied in inventory valuation, and Note 6(4) for details of inventories. As at December 31, 2025, the balances of inventory and allowance for inventory valuation losses were \$1,865,912 thousand and \$391,038 thousand, respectively.

The Company is primarily engaged in manufacturing and sales of API. Due to the complex manufacturing process, long lead time in materials preparation and uncertain product registration timing before market launch, there is a higher risk of incurring loss on inventory valuation. For inventories sold under normal terms, the Company measures inventories at the lower of cost and net realisable value. For inventories ageing over a certain period of time or are individually identified as obsolete inventories, the net realisable value is calculated based on the historical information of inventory turnover. Since the calculation of net realisable value involves subjective judgement and the ending balance of inventory is material to the financial statements, we considered the valuation of inventory a key audit matter.

#### How our audit addressed the matter

We performed the following key audit procedures in response to the above key audit matter:

1. We compared the financial statements to ascertain whether the provision policy on allowance for inventory valuation losses has been consistently applied and assessed the reasonableness of the provision policy.
2. We understood the inventory management process, observing annual physical counts to assess the effectiveness of management's classification and controls over obsolete and slow-moving inventory.
3. We sampled and verified the accuracy of inventory aging report and evaluated whether the older inventories were obsolete.
4. We sampled the computation of net realisable value of individual inventory and compared with account records.

## ***Responsibilities of management and those charged with governance for the parent company only financial statements***

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee, are responsible for overseeing the Company's financial reporting process.

## ***Auditors' responsibilities for the audit of the parent company only financial statements***

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a

going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Yeh, Fang-Ting

Independent Accountants

Hsu, Hui-Yu

PricewaterhouseCoopers, Taiwan

Republic of China

March 4, 2026

---

The accompanying parent company only financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying parent company only financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

SCINOPHARM TAIWAN, LTD.  
PARENT COMPANY ONLY BALANCE SHEETS  
DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

Assets	Notes	December 31, 2025		December 31, 2024		
		AMOUNT	%	AMOUNT	%	
<b>Current assets</b>						
1100	Cash and cash equivalents	6(1)	\$ 3,025,333	26	\$ 4,068,213	35
1110	Financial assets at fair value through profit or loss - current	6(2)	90	-	-	-
1140	Contract assets - current	6(17)	-	-	29,397	-
1170	Accounts receivable, net	6(3) and 12	594,508	5	581,284	5
1200	Other receivables		10,655	-	19,238	-
1210	Other receivables - related parties	7	2,699	-	3,720	-
130X	Inventories	5 and 6(4)	1,474,874	13	1,512,887	13
1410	Prepayments		106,860	1	100,938	1
11XX	<b>Total current assets</b>		<u>5,215,019</u>	<u>45</u>	<u>6,315,677</u>	<u>54</u>
<b>Non-current assets</b>						
1517	Financial assets at fair value through other comprehensive income - non-current	6(5)	1,367,738	12	70,134	1
1550	Investments accounted for using equity method	6(6)	1,407,800	12	1,556,076	13
1600	Property, plant and equipment	6(7)(9) and 7	2,263,728	20	2,489,060	21
1755	Right-of-use assets	6(8)	611,247	5	621,860	5
1780	Intangible assets		9,467	-	11,328	-
1840	Deferred income tax assets	6(24)	563,647	5	524,419	5
1915	Prepayments for equipment	6(7)	137,306	1	149,977	1
1920	Guarantee deposits paid		1,551	-	848	-
1980	Other financial assets - non-current	6(1) and 8	29,270	-	30,940	-
1990	Other non-current assets		41,386	-	-	-
15XX	<b>Total non-current assets</b>		<u>6,433,140</u>	<u>55</u>	<u>5,454,642</u>	<u>46</u>
1XXX	<b>Total assets</b>		<u>\$ 11,648,159</u>	<u>100</u>	<u>\$ 11,770,319</u>	<u>100</u>

(Continued)

SCINOPHARM TAIWAN, LTD.  
PARENT COMPANY ONLY BALANCE SHEETS  
DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity	Notes	December 31, 2025		December 31, 2024		
		AMOUNT	%	AMOUNT	%	
<b>Current liabilities</b>						
2120	Financial liabilities at fair value through profit or loss - current	6(2)	\$ -	-	\$ 1,225	-
2130	Contract liabilities - current	6(17)	104,039	1	118,413	1
2150	Notes payable		12	-	1,211	-
2170	Accounts payable		51,578	-	51,840	1
2180	Accounts payable - related parties	7	1,229	-	31,261	-
2200	Other payables	6(10) and 7	306,248	3	362,560	3
2230	Current income tax liabilities	6(24)	14,488	-	11,479	-
2280	Lease liabilities - current		23,461	-	19,638	-
21XX	<b>Total current liabilities</b>		<u>501,055</u>	<u>4</u>	<u>597,627</u>	<u>5</u>
<b>Non-current liabilities</b>						
2570	Deferred income tax liabilities	6(24)	628	-	1,304	-
2580	Lease liabilities - non-current		608,777	6	620,342	6
2640	Net defined benefit liabilities - non-current	6(11)	10,694	-	23,614	-
2645	Guarantee deposits received		2,268	-	1,628	-
25XX	<b>Total non-current liabilities</b>		<u>622,367</u>	<u>6</u>	<u>646,888</u>	<u>6</u>
2XXX	<b>Total liabilities</b>		<u>1,123,422</u>	<u>10</u>	<u>1,244,515</u>	<u>11</u>
<b>Equity</b>						
Share capital						
3110	Common stock	6(12)	7,907,392	68	7,907,392	67
3200	Capital surplus	6(13)	1,294,689	11	1,294,689	10
Retained earnings						
3310	Legal reserve	6(15)	817,709	7	783,817	7
3320	Special reserve		126,177	1	185,856	2
3350	Unappropriated earnings		366,455	3	480,227	4
3400	Other equity interest	6(16)	12,315	-	(126,177)	(1)
3XXX	<b>Total equity</b>		<u>10,524,737</u>	<u>90</u>	<u>10,525,804</u>	<u>89</u>
Significant contingent liabilities and unrecognised contract commitments						
3X2X	<b>Total liabilities and equity</b>		<u>\$ 11,648,159</u>	<u>100</u>	<u>\$ 11,770,319</u>	<u>100</u>

The accompanying notes are an integral part of these parent company only financial statements.

**SCINOPHARM TAIWAN, LTD.**  
**PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME**  
**YEARS ENDED DECEMBER 31, 2025 AND 2024**

(Expressed in thousands of New Taiwan dollars, except for earnings per share amount)

	Items	Notes	Year ended December 31			
			2025		2024	
			AMOUNT	%	AMOUNT	%
4000	Operating revenue	6(17) and 7	\$ 3,108,908	100	\$ 3,139,056	100
5000	Operating costs	6(4)(11)(22)(23) and 7	( 2,006,119)	( 65)	( 2,002,206)	( 64)
5900	Net operating margin		<u>1,102,789</u>	<u>35</u>	<u>1,136,850</u>	<u>36</u>
	Operating expenses	6(7)(11)(22)(23), 7 and 12				
6100	Selling expenses		( 130,037)	( 4)	( 145,448)	( 5)
6200	General and administrative expenses		( 288,402)	( 9)	( 292,596)	( 9)
6300	Research and development expenses		( 437,265)	( 14)	( 395,942)	( 12)
6450	Expected credit gain (loss)		<u>31</u>	<u>-</u>	<u>( 1,814)</u>	<u>-</u>
6000	Total operating expenses		<u>( 855,673)</u>	<u>( 27)</u>	<u>( 835,800)</u>	<u>( 26)</u>
6900	Operating profit		<u>247,116</u>	<u>8</u>	<u>301,050</u>	<u>10</u>
	Non-operating income and expenses					
7100	Interest income	6(18)	53,004	2	60,930	2
7010	Other income	6(5)(19) and 7	33,592	1	11,289	-
7020	Other gains and losses	6(2)(9)(20) and 12	( 33,940)	( 1)	6,035	-
7050	Finance costs	6(8)(21)	( 7,282)	-	( 7,292)	-
7070	Share of (loss) profit of subsidiaries, associates and joint ventures accounted for using equity method	6(6)	( 145,164)	( 5)	40,922	1
7000	Total non-operating income and expenses		<u>( 99,790)</u>	<u>( 3)</u>	<u>111,884</u>	<u>3</u>
7900	Profit before income tax		147,326	5	412,934	13
7950	Income tax expense	6(24)	( 10,375)	( 1)	( 73,584)	( 2)
8200	Profit for the year		<u>\$ 136,951</u>	<u>4</u>	<u>\$ 339,350</u>	<u>11</u>
	<b>Other comprehensive income (loss)</b>					
	<b>Components of other comprehensive income (loss) that will not be reclassified to profit or loss</b>					
8311	Actuarial gains (losses) on defined benefit plan	6(11)	\$ 311	-	( \$ 540)	-
8316	Unrealised gain from equity instruments measured at fair value through other comprehensive income	6(5)(16)	141,604	5	161	-
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	6(24)	( 62)	-	107	-
	<b>Components of other comprehensive income (loss) that will be reclassified to profit or loss</b>					
8361	Financial statements translation differences of foreign operations	6(6)(16)	( 3,112)	-	59,518	2
8300	Total other comprehensive income for the year		<u>\$ 138,741</u>	<u>5</u>	<u>\$ 59,246</u>	<u>2</u>
8500	Total comprehensive income for the year		<u>\$ 275,692</u>	<u>9</u>	<u>\$ 398,596</u>	<u>13</u>
	Earnings per share (in dollars)	6(25)				
9750	Basic		<u>\$ 0.17</u>		<u>\$ 0.43</u>	
9850	Diluted		<u>\$ 0.17</u>		<u>\$ 0.43</u>	

The accompanying notes are an integral part of these parent company only financial statements.

SCINOPHARM TAIWAN, LTD.  
PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY  
YEARS ENDED DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

	Notes	Retained Earnings				Other Equity Interest		Total	
		Share capital - common stock	Capital reserve	Legal reserve	Special reserve	Unappropriated earnings	Financial statements translation differences of foreign operations		Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income
<u>Year ended December 31, 2024</u>									
Balance at January 1, 2024		\$ 7,907,392	\$ 1,294,689	\$ 755,145	\$ 98,176	\$ 494,884	(\$ 88,156 )	(\$ 97,700 )	\$ 10,364,430
Net income for the year		-	-	-	-	339,350	-	-	339,350
Other comprehensive income (loss) for the year	6(5)(6)(16)	-	-	-	-	( 433 )	59,518	161	59,246
Total comprehensive income		-	-	-	-	338,917	59,518	161	398,596
Distribution of 2023 net income:									
Legal reserve		-	-	28,672	-	( 28,672 )	-	-	-
Special reserve		-	-	-	87,680	( 87,680 )	-	-	-
Cash dividends	6(15)	-	-	-	-	( 237,222 )	-	-	( 237,222 )
Balance at December 31, 2024		\$ 7,907,392	\$ 1,294,689	\$ 783,817	\$ 185,856	\$ 480,227	(\$ 28,638 )	(\$ 97,539 )	\$ 10,525,804
<u>Year ended December 31, 2025</u>									
Balance at January 1, 2025		\$ 7,907,392	\$ 1,294,689	\$ 783,817	\$ 185,856	\$ 480,227	(\$ 28,638 )	(\$ 97,539 )	\$ 10,525,804
Net income for the year		-	-	-	-	136,951	-	-	136,951
Other comprehensive income (loss) for the year	6(5)(6)(16)	-	-	-	-	249	( 3,112 )	141,604	138,741
Total comprehensive income (loss)		-	-	-	-	137,200	( 3,112 )	141,604	275,692
Distribution of 2024 net income:									
Legal reserve		-	-	33,892	-	( 33,892 )	-	-	-
Cash dividends	6(15)	-	-	-	-	( 276,759 )	-	-	( 276,759 )
Reversal of special reserve		-	-	-	( 59,679 )	59,679	-	-	-
Balance at December 31, 2025		\$ 7,907,392	\$ 1,294,689	\$ 817,709	\$ 126,177	\$ 366,455	(\$ 31,750 )	\$ 44,065	\$ 10,524,737

The accompanying notes are an integral part of these parent company only financial statements.

SCINOPHARM TAIWAN, LTD.  
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS  
YEARS ENDED DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

	Notes	Year ended December 31	
		2025	2024
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit before tax		\$ 147,326	\$ 412,934
Adjustments			
Adjustments to reconcile profit (loss)			
(Gain) loss on valuation of financial assets and liabilities at fair value through profit or loss		( 1,315 )	9,529
Expected credit (gain) loss	12	( 31 )	1,814
Loss on (gain on reversal of) inventory market price decline	6(4)	67,282	( 897 )
Share of loss (profit) of subsidiaries, associates and joint ventures accounted for using equity method	6(6)	145,164	( 40,922 )
Depreciation of property, plant and equipment	6(7)(22)	362,038	354,080
Depreciation of right-of-use assets	6(8)(22)	18,854	15,422
Property, plant and equipment transferred to loss	6(7)	-	119
(Gain) loss on disposal of property, plant and equipment	6(20)	( 119 )	682
(Gain on reversal of) impairment loss	6(7)(9)(20)	( 2,251 )	1,119
Amortisation	6(22)	17,139	5,994
Interest income	6(18)	( 53,004 )	( 60,930 )
Dividend income	6(5)(19)	( 25,615 )	-
Interest expense	6(21)	7,282	7,292
Changes in operating assets and liabilities			
Changes in operating assets			
Contract assets - current		29,397	( 29,397 )
Accounts receivable		( 13,193 )	197,957
Other receivables		6,672	( 3,105 )
Other receivables - related parties		1,021	( 760 )
Inventories		( 33,089 )	( 142,550 )
Prepayments		( 2,102 )	( 8,827 )
Changes in operating liabilities			
Contract liabilities - current		( 14,374 )	30,530
Notes payable		( 1,199 )	33
Accounts payable		( 262 )	( 16,523 )
Accounts payable - related parties		( 30,032 )	( 12,022 )
Other payables		( 27,052 )	13,222
Net defined benefit liabilities - non-current		( 12,609 )	( 31,440 )
Cash inflow generated from operations		585,928	703,354
Interest received		54,915	60,230
Dividends received		25,615	-
Interest paid		( 7,282 )	( 7,292 )
Income tax paid		( 47,332 )	( 105,534 )
Net cash flows from operating activities		<u>611,844</u>	<u>650,758</u>

(Continued)

SCINOPHARM TAIWAN, LTD.  
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS  
YEARS ENDED DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

	Notes	Year ended December 31	
		2025	2024
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of financial assets at fair value through other comprehensive income - non-current		( \$ 1,156,000 )	\$ -
Cash paid for acquisition of property, plant and equipment	6(26)	( 68,398 )	( 85,965 )
Proceeds from disposal of property, plant and equipment		119	-
Acquisition of intangible assets		( 4,932 )	( 5,639 )
Increase in prepayments for equipment	6(26)	( 134,378 )	( 104,257 )
Increase in guarantee deposits paid		( 703 )	( 21 )
Decrease in other financial assets - non-current		1,670	-
Net cash flows used in investing activities		( <u>1,362,622</u> )	( <u>195,882</u> )
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Repayment of the principal portion of lease liabilities	6(27)	( 15,983 )	( 12,472 )
Increase in guarantee deposits received	6(27)	640	1,628
Payment of cash dividends	6(15)	( <u>276,759</u> )	( <u>237,222</u> )
Net cash flows used in financing activities		( <u>292,102</u> )	( <u>248,066</u> )
Net (decrease) increase in cash and cash equivalents		( 1,042,880 )	206,810
Cash and cash equivalents at beginning of year	6(1)	<u>4,068,213</u>	<u>3,861,403</u>
Cash and cash equivalents at end of year	6(1)	<u>\$ 3,025,333</u>	<u>\$ 4,068,213</u>

The accompanying notes are an integral part of these parent company only financial statements.

## **Appendix 4**

### INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of ScinoPharm Taiwan, Ltd.

#### ***Opinion***

We have audited the accompanying consolidated balance sheets of ScinoPharm Taiwan, Ltd. and subsidiaries (the "Group") as at December 31, 2025 and 2024, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of material accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission.

#### ***Basis for opinion***

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the *Auditors' responsibilities for the audit of the consolidated financial statements* section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountants of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### ***Key audit matters***

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Group's 2025 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

The key audit matters for the Group's 2025 consolidated financial statements are stated as follows:

#### ***Occurrence of sales revenues from API and injection products***

##### Description

Refer to Note 4(27) for accounting policy on revenue recognition and Note 6(17) for accounting items on revenue.

The Group's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient ("API") and injection products. The Group's customers come from Taiwan, Asia, Europe and America. Since the volume and amount of transactions are significant, we considered the occurrence of sales revenue from API and injection products a key audit matter.

#### How our audit addressed the matter

We performed the following key audit procedures in response to the above key audit matter:

1. We evaluated the internal control system that was designed and implemented by management in reviewing customers' credit, and tested whether the counterparty and the credit valuation documents have been properly approved.
2. We sampled transaction details and supporting documents for consistency from transaction counterparties who have higher turnover growth.
3. We sent confirmation letters for significant year-end accounts receivable, ascertained whether the responses and account records were consistent with customers' data, and evaluated the reasonableness on the difference between the responses and the account records.

#### ***Inventory valuation***

##### Description

Refer to Note 4(12) for accounting policies on inventory valuation, Note 5(2) for the uncertainty of accounting estimates and assumptions applied in inventory valuation, and Note 6(4) for details of inventories. As at December 31, 2025, the balances of inventory and allowance for inventory valuation losses were \$2,117,946 thousand and \$481,406 thousand, respectively.

The Group is primarily engaged in the manufacture and sales of API. Due to the complex manufacturing process, long lead time in materials preparation and uncertain product registration timing before market launch, there is a higher risk of incurring loss on inventory valuation. For inventories sold under normal terms, the Group measures inventories at the lower of cost and net realisable value. For inventories ageing over a certain period of time or are individually identified as obsolete inventories, the net realisable value is calculated based on the historical information of inventory turnover. Since the calculation of net realisable value involves subjective judgement and the ending balance of inventory is material to the financial statements, we considered the valuation of inventory a key audit matter.

#### How our audit addressed the matter

We performed the following key audit procedures in response to the above key audit matter:

1. We compared the financial statements to ascertain whether the provision policy on allowance for inventory valuation losses has been consistently applied and assessed the reasonableness of the provision policy.
2. We understood the inventory management process, observing annual physical counts to assess the effectiveness of management's classification and controls over obsolete and slow-moving inventory.
3. We sampled and verified the accuracy of inventory ageing report and evaluated whether the older inventories were obsolete.
4. We sampled the computation of net realisable value of individual inventory and compared with account records.

#### ***Other matter – Parent company only financial reports***

We have audited and expressed an unmodified opinion on the parent company only financial statements of ScinoPharm Taiwan, Ltd. as at and for the years ended December 31, 2025 and 2024.

#### ***Responsibilities of management and those charged with governance for the***

## ***consolidated financial statements***

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee, are responsible for overseeing the Group's financial reporting process.

## ***Auditors' responsibilities for the audit of the consolidated financial statements***

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report.

However, future events or conditions may cause the Group to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Yeh, Fang-Ting

Independent Accountants

Hsu, Hui-Yu

PricewaterhouseCoopers, Taiwan

Republic of China

March 4, 2026

---

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS  
DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

Assets	Notes	December 31, 2025		December 31, 2024		
		AMOUNT	%	AMOUNT	%	
<b>Current assets</b>						
1100	Cash and cash equivalents	6(1)	\$ 3,110,074	26	\$ 4,165,987	35
1110	Financial assets at fair value through profit or loss - current	6(2)	90	-	-	-
1140	Contract assets - current	6(17)	-	-	29,397	-
1170	Accounts receivable, net	6(3) and 12	612,411	5	604,219	5
1200	Other receivables		11,616	-	20,572	-
130X	Inventories	5 and 6(4)	1,636,540	14	1,673,007	14
1410	Prepayments		119,990	1	114,908	1
11XX	<b>Total current assets</b>		<u>5,490,721</u>	<u>46</u>	<u>6,608,090</u>	<u>55</u>
<b>Non-current assets</b>						
1517	Financial assets at fair value through other comprehensive income - non-current	6(5)	1,367,738	12	70,134	1
1600	Property, plant and equipment	6(6)(8) and 7	3,408,782	29	3,738,889	32
1755	Right-of-use assets	6(7)	674,278	6	686,635	6
1780	Intangible assets	6(6)	15,363	-	17,130	-
1840	Deferred income tax assets	5 and 6(24)	664,626	6	625,260	5
1915	Prepayments for equipment	6(6)	144,633	1	150,890	1
1920	Guarantee deposits paid		3,022	-	2,367	-
1980	Other financial assets - non-current	6(1) and 8	29,270	-	30,940	-
1990	Other non-current assets	6(6)	59,292	-	12,403	-
15XX	<b>Total non-current assets</b>		<u>6,367,004</u>	<u>54</u>	<u>5,334,648</u>	<u>45</u>
1XXX	<b>Total assets</b>		<u>\$ 11,857,725</u>	<u>100</u>	<u>\$ 11,942,738</u>	<u>100</u>

(Continued)

**SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES**  
**CONSOLIDATED BALANCE SHEETS**  
**DECEMBER 31, 2025 AND 2024**  
(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity	Notes	December 31, 2025		December 31, 2024		
		AMOUNT	%	AMOUNT	%	
<b>Current liabilities</b>						
2100	Short-term borrowings	6(9)	\$ 130,424	1	\$ 35,563	-
2120	Financial liabilities at fair value through profit or loss - current	6(2)	-	-	1,225	-
2130	Contract liabilities - current	6(17)	115,351	1	119,396	1
2150	Notes payable		12	-	1,211	-
2170	Accounts payable		62,515	1	80,959	1
2200	Other payables	6(10)	363,581	3	498,191	4
2230	Current income tax liabilities	6(24)	14,499	-	11,499	-
2280	Lease liabilities - current		23,461	-	19,638	-
21XX	<b>Total current liabilities</b>		<u>709,843</u>	<u>6</u>	<u>767,682</u>	<u>6</u>
<b>Non-current liabilities</b>						
2570	Deferred income tax liabilities	6(24)	628	-	1,304	-
2580	Lease liabilities - non-current		608,777	5	620,342	5
2640	Net defined benefit liabilities - non-current	6(11)	10,694	-	23,614	1
2645	Guarantee deposits received		3,046	-	3,992	-
25XX	<b>Total non-current liabilities</b>		<u>623,145</u>	<u>5</u>	<u>649,252</u>	<u>6</u>
2XXX	<b>Total liabilities</b>		<u>1,332,988</u>	<u>11</u>	<u>1,416,934</u>	<u>12</u>
<b>Equity attributable to owners of parent</b>						
Share capital						
3110	Common stock	6(12)	7,907,392	67	7,907,392	66
3200	Capital surplus	6(13)	1,294,689	11	1,294,689	10
Retained earnings						
3310	Legal reserve	6(15)	817,709	7	783,817	7
3320	Special reserve		126,177	1	185,856	2
3350	Unappropriated earnings		366,455	3	480,227	4
3400	Other equity interest	6(16)	12,315	-	(126,177)	(1)
3XXX	<b>Total equity</b>		<u>10,524,737</u>	<u>89</u>	<u>10,525,804</u>	<u>88</u>
Significant contingent liabilities and unrecognised contract commitments						
3X2X	<b>Total liabilities and equity</b>		<u>\$ 11,857,725</u>	<u>100</u>	<u>\$ 11,942,738</u>	<u>100</u>

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME  
YEARS ENDED DECEMBER 31, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars, except for earnings per share amount)

	Items	Notes	Year ended December 31			
			2025		2024	
			AMOUNT	%	AMOUNT	%
4000	Operating revenue	6(17)	\$ 3,163,422	100	\$ 3,406,284	100
5000	Operating costs	6(4)(11)(22)(23)	( 2,066,983)	( 66)	( 2,106,074)	( 62)
5900	Net operating margin		<u>1,096,439</u>	<u>34</u>	<u>1,300,210</u>	<u>38</u>
	Operating expenses	6(7)(11)(22)(23), 7 and 12				
6100	Selling expenses		( 127,049)	( 4)	( 141,723)	( 4)
6200	General and administrative expenses		( 363,248)	( 11)	( 376,420)	( 11)
6300	Research and development expenses		( 497,277)	( 16)	( 459,358)	( 14)
6450	Expected credit gain (loss)		41	-	( 1,668)	-
6000	Total operating expenses		<u>( 987,533)</u>	<u>( 31)</u>	<u>( 979,169)</u>	<u>( 29)</u>
6900	Operating profit		<u>108,906</u>	<u>3</u>	<u>321,041</u>	<u>9</u>
	Non-operating income and expenses					
7100	Interest income	6(18)	53,376	1	61,521	2
7010	Other income	6(5)(19)	30,444	1	29,894	1
7020	Other gains and losses	6(2)(8)(20) and 12	( 35,484)	( 1)	8,644	-
7050	Finance costs	6(7)(21)	( 9,867)	-	( 8,083)	-
7000	Total non-operating income and expenses		<u>38,469</u>	<u>1</u>	<u>91,976</u>	<u>3</u>
7900	<b>Profit before income tax</b>		<u>147,375</u>	<u>4</u>	<u>413,017</u>	<u>12</u>
7950	Income tax expense	6(24)	( 10,424)	-	( 73,667)	( 2)
8200	<b>Profit for the year</b>		<u>\$ 136,951</u>	<u>4</u>	<u>\$ 339,350</u>	<u>10</u>
	<b>Other comprehensive income (loss)</b>					
	<b>Components of other comprehensive income (loss) that will not be reclassified to profit or loss</b>					
8311	Actuarial gains (losses) on defined benefit plans	6(11)	\$ 311	-	( \$ 540)	-
8316	Unrealised gain from equity instruments measured at fair value through other comprehensive income	6(5)(16)	141,604	5	161	-
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	6(24)	( 62)	-	107	-
	<b>Components of other comprehensive income (loss) that will be reclassified to profit or loss</b>					
8361	Financial statements translation differences of foreign operations	6(16)	( 3,112)	-	59,518	2
8300	<b>Total other comprehensive income for the year</b>		<u>\$ 138,741</u>	<u>5</u>	<u>\$ 59,246</u>	<u>2</u>
8500	<b>Total comprehensive income for the year</b>		<u>\$ 275,692</u>	<u>9</u>	<u>\$ 398,596</u>	<u>12</u>
	Profit attributable to:					
8610	Owners of the parent		<u>\$ 136,951</u>	<u>4</u>	<u>\$ 339,350</u>	<u>10</u>
	Comprehensive income attributable to:					
8710	Owners of the parent		<u>\$ 275,692</u>	<u>9</u>	<u>\$ 398,596</u>	<u>12</u>
	Earnings per share (in dollars)	6(25)				
9750	Basic		<u>\$ 0.17</u>		<u>\$ 0.43</u>	
9850	Diluted		<u>\$ 0.17</u>		<u>\$ 0.43</u>	

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
YEARS ENDED DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

	Equity attributable to owners of the parent							Total equity	
	Notes	Retained Earnings				Other Equity Interest			
		Share capital - common stock	Capital reserve	Legal reserve	Special reserve	Unappropriated earnings	Financial statements translation differences of foreign operations		Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income
<u>Year ended December 31, 2024</u>									
Balance at January 1, 2024		\$ 7,907,392	\$ 1,294,689	\$ 755,145	\$ 98,176	\$ 494,884	(\$ 88,156 )	(\$ 97,700 )	\$ 10,364,430
Net income for the year		-	-	-	-	339,350	-	-	339,350
Other comprehensive income (loss) for the year	6(5)(16)	-	-	-	-	( 433 )	59,518	161	59,246
Total comprehensive income for the year		-	-	-	-	338,917	59,518	161	398,596
Distribution of 2023 net income:									
Legal reserve		-	-	28,672	-	( 28,672 )	-	-	-
Special reserve		-	-	-	87,680	( 87,680 )	-	-	-
Cash dividends	6(15)	-	-	-	-	( 237,222 )	-	-	( 237,222 )
Balance at December 31, 2024		\$ 7,907,392	\$ 1,294,689	\$ 783,817	\$ 185,856	\$ 480,227	(\$ 28,638 )	(\$ 97,539 )	\$ 10,525,804
<u>Year ended December 31, 2025</u>									
Balance at January 1, 2025		\$ 7,907,392	\$ 1,294,689	\$ 783,817	\$ 185,856	\$ 480,227	(\$ 28,638 )	(\$ 97,539 )	\$ 10,525,804
Net income for the year		-	-	-	-	136,951	-	-	136,951
Other comprehensive income (loss) for the year	6(5)(16)	-	-	-	-	249	( 3,112 )	141,604	138,741
Total comprehensive income (loss) for the year		-	-	-	-	137,200	( 3,112 )	141,604	275,692
Distribution of 2024 net income:									
Legal reserve		-	-	33,892	-	( 33,892 )	-	-	-
Cash dividends	6(15)	-	-	-	-	( 276,759 )	-	-	( 276,759 )
Reversal of special reserve		-	-	-	( 59,679 )	59,679	-	-	-
Balance at December 31, 2025		\$ 7,907,392	\$ 1,294,689	\$ 817,709	\$ 126,177	\$ 366,455	(\$ 31,750 )	\$ 44,065	\$ 10,524,737

The accompanying notes are an integral part of these consolidated financial statements.

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
YEARS ENDED DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

	Notes	Year ended December 31	
		2025	2024
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit before tax		\$ 147,375	\$ 413,017
Adjustments			
Adjustments to reconcile profit (loss)			
(Gain) loss on valuation of financial assets and liabilities at fair value through profit or loss		( 1,315 )	9,529
Expected credit (gain) loss	12	( 41 )	1,668
Loss on inventory market price decline	6(4)	65,207	9,978
Depreciation of property, plant and equipment	6(6)(22)	475,671	461,545
Depreciation of right-of-use assets	6(7)(22)	20,620	17,241
Property, plant and equipment transferred to loss	6(6)	-	119
(Gain on reversal of) impairment loss	6(6)(8)(20)	( 2,251 )	1,119
Loss on disposal of property, plant and equipment	6(20)	185	4,636
Amortisation	6(22)	20,437	9,495
Interest income	6(18)	( 53,376 )	( 61,521 )
Dividend income	6(5)(19)	( 25,615 )	-
Interest expense	6(21)	9,867	8,083
Changes in operating assets and liabilities			
Changes in operating assets			
Contract assets - current		29,397	( 29,397 )
Accounts receivable		( 8,151 )	182,329
Other receivables		7,045	5,358
Inventories		( 32,608 )	( 175,181 )
Prepayments		( 1,274 )	( 7,936 )
Changes in operating liabilities			
Contract liabilities - current		( 4,045 )	8,429
Notes payable		( 1,199 )	32
Accounts payable		( 18,444 )	( 20,319 )
Other payables		( 42,693 )	( 3,025 )
Net defined benefit liabilities - non-current		( 12,609 )	( 31,440 )
Cash inflow generated from operations		572,183	803,759
Interest received		55,287	60,821
Dividends received		25,615	-
Interest paid		( 9,788 )	( 8,069 )
Income tax paid		( 47,389 )	( 105,598 )
Net cash flows from operating activities		<u>595,908</u>	<u>750,913</u>

(Continued)

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
YEARS ENDED DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

	Notes	Year ended December 31	
		2025	2024
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of financial assets at fair value through other comprehensive income - non-current		( \$ 1,156,000 )	\$ -
Cash paid for acquisition of property, plant and equipment	6(26)	( 145,375 )	( 114,877 )
Proceeds from disposal of property, plant and equipment		1,463	6,218
Acquisition of intangible assets		( 4,948 )	( 8,563 )
Cash paid for prepayments for equipment	6(26)	( 145,914 )	( 165,292 )
(Increase) decrease in guarantee deposits paid		( 655 )	86
Decrease in other financial assets - non-current		1,670	-
Increase in other non-current assets		( 1,737 )	( 10,955 )
Net cash flows used in investing activities		( 1,451,496 )	( 293,383 )
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Increase in short-term borrowings	6(27)	141,372	35,326
Decrease in short-term borrowings	6(27)	( 50,039 )	( 33,156 )
Repayment of the principal portion of lease liabilities	6(27)	( 15,983 )	( 12,472 )
(Decrease) increase in guarantee deposits received	6(27)	( 890 )	2,637
Payment of cash dividends	6(15)	( 276,759 )	( 237,222 )
Net cash flows used in financing activities		( 202,299 )	( 244,887 )
Effect of foreign exchange rate changes		1,974	11,820
Net (decrease) increase in cash and cash equivalents		( 1,055,913 )	224,463
Cash and cash equivalents at beginning of year	6(1)	4,165,987	3,941,524
Cash and cash equivalents at end of year	6(1)	\$ 3,110,074	\$ 4,165,987

The accompanying notes are an integral part of these consolidated financial statements.

## Appendix 5

### ScinoPharm Taiwan, Ltd. Earnings Distribution Plan for Fiscal Year 2025

Item	Amount (TWD)
After-tax net profit earned in 2025	\$ 136,950,700
Plus: Remeasurement of defined benefit plans	248,675
Less: Legal reserve	(13,719,938)
Plus: Reversal of Special reserve	103,346,860
Distributable profit from this period	<u>226,826,297</u>
Plus: Accumulated undistributed earnings from previous period	<u>229,255,686</u>
Total distributable earnings as of this period	<u>456,081,983</u>
Dividends to shareholders (Cash dividend TWD 290 on each 1,000 shares held)	<u>(229,314,375)</u>
Undistributed earnings as of the end of the period	<u>\$ 226,767,608</u>

Notes:

1. In terms of earnings distribution for fiscal year 2025, priority is given to distributing the earnings posted in the given fiscal year while retained earnings from the previous fiscal year is drawn on to make up for any deficiency.
2. The actual amount of cash dividend paid to the shareholders shall be paid up to the number rounded down to the nearest dollar with the fraction (if any) to be accounted as Other Income of the Company.

Chairperson : Chih-Hsien Lo

CEO : Li-An Lu

Chief Accountant : Yao-Hui Wang

**Appendix 6**

**ScinoPharm Taiwan, Ltd.**

**Contrast Table for amendments to the Articles of Incorporation**

Current Provision	Revision Proposed	Remark
<p>Article 23</p> <p>The Company will have <u>seventeen (17)</u> Directors to be elected by the Shareholders' Meeting from the shareholders with disposing capacity. <u>Two or more</u> of the above Directors shall be independent directors, and the total number of independent directors shall account for not less than one <u>fifth (1/5)</u> of the total number of directors. Directors are to be elected by the Shareholders' Meeting from among the candidates nominated.</p> <p>The special qualification, required shareholding, restriction on concurrent positions held, determination of impartiality, method of nomination and method of election of the independent directors and other relevant legally required matters shall be in accordance with the Company Act and the relevant laws and regulations prescribed by the competent securities authority.</p>	<p>Article 23</p> <p>The Company will have <u>twelve (12)</u> Directors to be elected by the Shareholders' Meeting from the shareholders with disposing capacity. <u>Three or more</u> of the above Directors shall be independent directors, and the total number of independent directors shall account for not less than one <u>third (1/3)</u> of the total number of directors.</p> <p>Directors are to be elected by the Shareholders' Meeting from among the candidates nominated.</p> <p>The special qualification, required shareholding, restriction on concurrent positions held, determination of impartiality, method of nomination and method of election of the independent directors and other relevant legally required matters shall be in accordance with the Company Act and the relevant laws and regulations prescribed by the competent securities authority.</p>	<p>In accordance with the Financial Supervisory Commission's "Corporate Governance 3.0 - Sustainable Development Blueprint" and Article 4 of the "Taiwan Stock Exchange Corporation Directions for Compliance with the Establishment of Board of Directors by TWSE Listed Companies and the Board's Exercise of Powers" : the number of independent directors shall not be less than three. Furthermore, starting in 2027, the number of independent directors of listed companies shall not be less than one-third of the total number of directors. To comply with regulatory requirements and corporate governance practices, the Company is revising the number of directors and the number and proportion of independent directors, and revising paragraphs 1 and 2 of this article.</p>

Current Provision	Revision Proposed	Remark
<p>Article 43            These Articles of Incorporation established on October 16, 1997, have been revised as follows:1st revision of March 17, 1998, 2nd revision of April 7, 1999, 3rd revision of July 21, 2000, 4th revision of December 3, 2001, 5th revision of June 13, 2002, 6th revision of March 13, 2003, 7th revision of June 30, 2003, 8th revision of June 30, 2003, 9th revision of May 14, 2004, 10th revision of June 3, 2005, 11th revision of October 3 2005, 12th revision of February 15, 2006, 13th revision of June 7, 2006, 14th revision of June 18, 2009, 15th revision of September 25, 2009, 16th revision of April 29, 2010, 17th revision of December 9, 2010, 18th revision of June 13, 2012, 19th revision of June 21, 201,3 20th revision of June 18, 2014, 21st revision of June 27, 2016, 21st revision of June 27, 2016, 22nd revision of June 27, 2018, 23rd revision of June 27, 2019, 24th revision of June 30,2020, 25th revision of May 30, 2022 and 26th revision of May 29,2023, and 27th revision of May 28,2025</p>	<p>Article 43            These Articles of Incorporation established on October 16, 1997, have been revised as follows:1st revision of March 17, 1998, 2nd revision of April 7, 1999, 3rd revision of July 21, 2000, 4th revision of December 3, 2001, 5th revision of June 13, 2002, 6th revision of March 13, 2003, 7th revision of June 30, 2003, 8th revision of June 30, 2003, 9th revision of May 14, 2004, 10th revision of June 3, 2005, 11th revision of October 3 2005, 12th revision of February 15, 2006, 13th revision of June 7, 2006, 14th revision of June 18, 2009, 15th revision of September 25, 2009, 16th revision of April 29, 2010, 17th revision of December 9, 2010, 18th revision of June 13, 2012, 19th revision of June 21, 201,3 20th revision of June 18, 2014, 21st revision of June 27, 2016, 21st revision of June 27, 2016, 22nd revision of June 27, 2018, 23rd revision of June 27, 2019, 24th revision of June 30,2020, 25th revision of May 30, 2022, 26th revision of May 29,2023, 27th revision of May 28,2025, <u>and 28th revision of May 27,2026</u></p>	<p>Revision dates have been added</p>

**Appendix 7**

**ScinoPharm Taiwan, Ltd.**

**Contrast table for Amendments to the Operational Procedures for Acquisition and Dispose of Assets**

Current Provision	Revision Proposed	Remarks
<p>Article 10 Procedures for Public announce and Report Under any of the following circumstances, a public company acquiring or disposing of assets shall publicly announce and report the relevant information on the FSC's designated website in the appropriate format as prescribed by regulations within 2 days counting inclusively from the date of occurrence of the event: 1.~3.(Omitted) 4. Where equipment or right-of-use assets thereof for business use are acquired or disposed of, and furthermore the transaction counterparty is not a related party, and the transaction amount meets any of the following criteria: A. <u>For a public company whose paid-in capital is less than NT\$10 billion</u>, the transaction amount reaches NT\$500 million or more. B. For a public company whose paid-in capital is NT\$10 billion or more, the transaction amount reaches NT\$1 billion or more. (Omitted)</p>	<p>Article 10 Procedures for Public announce and report Under any of the following circumstances, a public company acquiring or disposing of assets shall publicly announce and report the relevant information on the FSC's designated website in the appropriate format as prescribed by regulations within 2 days counting inclusively from the date of occurrence of the event: 1.~3.(Omitted) Where equipment or right-of-use assets thereof for business use are acquired or disposed of, and furthermore the transaction counterparty is not a related party, the transaction amount reaches NT\$500 million or more.</p>	<p>The FSC amended Article 31 of the "Regulations Governing the Acquisition and Disposal of Assets by Public Companies" on July 24, 2025, adding provisions to relax the public announcement and reporting standards for companies with paid-in capital of NT\$50 billion or more when acquiring or disposing of equipment for business use with non-related parties. Based on the company's paid-in capital and the regulatory announcement and reporting standards, and because the regulations for companies with paid-in capital of NT\$10 billion or more and the FSC's relaxed regulations for companies with paid-in capital of NT\$50 billion do not apply, the content of item 4 of the first paragraph of this article is amended.</p>
<p>Article 14 Formulation and revision The handling procedure was approved by shareholders' meeting on Sept. 25, 2009, with revisions passed by shareholders' meeting on June 13, 2012, June 21, 2013, June 16, 2014, June 27, 2017, June 27, 2019 and May 30, 2022.</p>	<p>Article 14 Formulation and revision The handling procedure was approved by shareholders' meeting on Sept. 25, 2009, with revisions passed by shareholders' meeting on June 13, 2012, June 21, 2013, June 16, 2014, June 27, 2017, June 27, 2019, May 30, 2022 and <u>May 27, 2026</u></p>	<p>Addition of revision date</p>

## Appendix 8

### Details of the Duties subject to releasing directors and independent Directors from Non-competition

Name	Current Position with Other Company
Uni-President Enterprises Corp. Representative Chih-Hsien Lo	<p><b>Chairman of :</b>            Uni-President Enterprises Corp., President Natural Industrial Corp., Uni-Prosperty Lifestyle Corp., Ton Yi Industrial Corp., Ttet Union Corporation, Prince Housing &amp; Development Corp., President Packaging Industrial Corp., Woongjin Foods Co., Ltd., Daeyoung Foods Co., Ltd., President International Development Corp., Uni-President China Holdings Ltd., Changjiagang President Nisshin Food Co., Ltd., Uni-President (Philippines) Corp., Uni-President (Thailand) Ltd., Uni-President (Vietnam) Co., Ltd., Uni-President Enterprises (China) Investment Co., Ltd., President Chain Store Corp., Uni-President Cold-Chain Corp., Presco Netmarketing, Inc., Uni-President Dream Parks Co., President Century Corp., President Property Corp., Nanlien International Corp., Tone Sang Construction Corp., Prince Real Estate Co., Times Square International Holding Co., Times Square International Stays Co., Times Square International Hotel Co., Uni-President Express Corp., Cheng-Shi Investment Holding Co.</p> <p><b>Vice Chairman of :</b> President Nisshin Corp.</p> <p><b>Director of :</b>            Uni-Wonder Corp., Uni-President Organics Corp., Uni-President Glass Industrial Co., Ltd., Cayman President Holdings Ltd., Kai Yu (BVI) Investment Co., Ltd., President Fair Development Corp., Uni-President Southeast Asia Holdings Ltd., Uni-President Asia Holdings Ltd., Uni-President Hong Kong Holdings Ltd., Champ Green Capital Co., Ltd., Champ Green (Shanghai) Consulting Co., Ltd., Uni-President Enterprises (Guangzhou) Co., Ltd., Uni-President Enterprises (Fuzhou) Co., Ltd., Uni-President Enterprises (Xinjiang) Food Co., Ltd., Uni-President Enterprises (Wuhan) Food Co., Ltd., Uni-President Enterprises (Kunshan) Food Co., Ltd., Uni-President Enterprises (Chengdu) Food Co., Ltd., Uni-President Enterprises (Shenyang) Co., Ltd., Uni-President Enterprises (Harbin) Co., Ltd., Uni-President Enterprises (Hefei) Co., Ltd., Uni-President Enterprises (Zhengzhou) Co., Ltd., Uni-President Enterprises (Beijing) Drink Co., Ltd., Uni-President Enterprises (Kunshan) Food Technology Co., Ltd., Uni-President Enterprises (Nanchang) Co.,Ltd., Uni-President (Shanghai) Trading Co., Ltd., Uni-President Enterprises (Kunming) Food Co., Ltd., Uni-Yantai Tongli Beverage Industries Co., Ltd., Uni-President Enterprises (Changsha) Co., Ltd., Uni-President (Bama) Mineral Water Co., Ltd., Uni-President Enterprises (Nanning) Co., Ltd., Uni-President Enterprises (Zhanjiang) Co., Ltd., Uni-President Enterprises (Chongqing) Co., Ltd., Uni-President Enterprises (Taizhou) Co., Ltd., Uni-President Enterprises (Akesu) Co., Ltd., Uni-President Enterprises (Changchun) Co., Ltd., Shanghai United Enterprise Management Consulting Co., Ltd., Uni-President (Shanghai) Pearly Century Co., Ltd., Uni-President Enterprises (Baiyin) Co., Ltd., Hainan President Enterprises Co., Ltd., Uni-President Enterprises (Guiyang) Co., Ltd., Uni-President Enterprises (Jinan) Co., Ltd., Uni-President Enterprises (Hangzhou) Co., Ltd., Uni-President</p>

Name	Current Position with Other Company
	<p>Enterprises (Wuxue) Mineral Water Co., Ltd., Shijiazhuang President Enterprises Co., Ltd., Uni-President Enterprises (Xuzhou) Co., Ltd., Uni-President Enterprises (Henan) Co., Ltd., Uni-President Trading (Kunshan) Co., Ltd., Uni-President Enterprises (Shaanxi) Co., Ltd. Uni-President Enterprises (Jiangsu) Co., Ltd., Uni-President Enterprises (Changbai Mountain Jilin) Mineral Water Co., Ltd., President Enterprises (Kunshan) Real Estate Development Co., Ltd., Uni-President Enterprises (Shanghai) Co., Ltd., Uni-President Enterprises (Inner Mongolia) Co., Ltd., Uni-President Enterprises (Shanxi) Co., Ltd., Uni-President Enterprise (Hutubi) Tomato Products Technology Co., Ltd., Uni-President Enterprises (Shanghai) Drink &amp; Food Co., Ltd., Uni-President Enterprises (Tianjin) Co., Ltd., Uni-Oao Travel Service Corp., President Packaging Holdings Ltd., Kuang Chuan Dairy Co., Ltd., Kuang Chuan Foods Ltd., Uni-President Development Corp., President Professional Baseball Team Corp., Tait Marketing &amp; Distribution Co., Ltd., Wei Lih Food Industrial Co., Ltd., Howard Beach Resort Kenting Co., President Chain Store (BVI) Holdings Ltd., President Chain Store (Labuan) Holdings Ltd., Retail Support International Corp., Uni-President Asset Holdings Ltd., Kao Chuan Inv. Co., Ltd.</p> <p><b>Supervisor of :</b>  Infinity Holdings Ltd., Eternity Holdings Ltd.,  Celestial Prosperities Holdings Ltd.</p> <p><b>President of :</b> Presco Netmarketing Inc., Uni-President Express Corp.</p>
Kao Chyuan Inv. Corp. Representative: Shiow-Ling Kao	<p><b>Chairman of :</b>  Kao Chuan Inv. Co., Ltd. President Being Corp., President Fair Development Corp., Uni-President Department Store Corp., President Pharmaceutical Corp., President Drugstore Business Corp., Infinity Holdings Ltd., Eternity Holdings Ltd., Celestial Prosperities Holdings Ltd.</p> <p><b>Director of :</b>  Uni-President Enterprises Corp., President Chain Store Corp., Ton Yi Industrial Corp., Prince Housing &amp; Development Corp., President International Development Corp., Uni-President Development Corp., Times Square International Hotel Co., Uni-Wonder Corp., President Century Corp., Times Square International Holding Co., President Natural Industrial Corp., Uni-President Organics Corp.</p> <p><b>President of :</b>  President Fair Development Corp. 、 Kao Chuan Inv. Co., Ltd.</p>

Name	Current Position with Other Company
Tainan Spinning Co., Ltd. Representative: Po-Ming Hou	<p><b>President of :</b> Tainan Spinning Co., Ltd.(Vietnam), Tainan Textile Co.</p> <p><b>Chairman of :</b> Tainan Spinning Co., Ltd., Nan Fan Housing Development Co., Nan-Fan International Investment (Cayman), Ltd., Tainan Textile Co., Ltd. (Singapore), Yu Peng Investment Co., Ltd., Tainan Spinning Cultural and Educational Foundation., Tainan Spinning Retail &amp; Distribution Co., Ltd., New Yupeng Investment Co., Ltd., Chi-Liou Investment Co., Ltd.</p> <p><b>Director of :</b> Nantex Industry Co., Ltd., Nanfang Development Co., Ltd., Tainan Spinning Holdings (Cayman Islands) Co., Ltd., Prince Housing &amp; Development Corp., Uni-President Enterprises Corp., President International Development Corp., Howard Beach Resort Kenting Co., Ltd., T.Y. President Corp. (US)</p>
Uni-President Enterprises Corp. Representative: Tsung-Pin Wu	<p><b>Chairman of :</b> Tung –Ren Pharmaceutical Corp., Kai Nan Investment Co.,</p> <p><b>Director of :</b> Uni-Prosperity Lifestyle Corp., Prince Housing &amp; Development Corp., Grand Bills Finance Corp., President Fair Development Corp., President International Development Corp., Uni-President (Vietnam) Co., Ltd., Uni-President Hong Kong Holdings Ltd., President Chain Store Corp., Kuang Chuan Dairy Co., Ltd., Kuang Chuan Foods Ltd., Tung Lo Development Co., Ltd., Tone Sang Construction Corp., Prince Real Estate Co., Times Square International Holding Co., Times Square International Hotel Co. Cheng-Shi Investment Holding Co.</p> <p><b>Supervisor of :</b> President Kikkoman Inc., Woongjin Foods Co., Ltd., Daeyoung Foods Co., Ltd., Uni-President (Korea) Co., Ltd., Kunshan President Kikkoman Biotechnology Co., Ltd., President Kikkoman Zhenji Foods Co., Ltd., President Century Corp., President Professional Baseball Team Corp., Nanlien International Corp., Times Square International Stays Co., PAYUNi co. Ltd., Uni-President Express Corp. Ltd.,</p>
Uni-President Enterprises Corp. Representative: Jia-Horng Guo	<p><b>Vice Chairman of :</b> Taishin Securities Co., Ltd.</p> <p><b>Director of :</b> Accelerate Private Machine Intelligence Co.</p> <p><b>Supervisor of:</b> Standard Motor Corp., Dynasty Techwood Corp., Taipei Exchange</p> <p><b>Director of :</b> Taiwan Securities Association</p>
President International Development Corp.	<p><b>Chairman of :</b> President Life Sciences Co., Ltd., AndroSciences Corp.</p> <p><b>Director of :</b> Allianz Pharmascience Ltd., RenalPro Medical, Inc.</p>

Name	Current Position with Other Company
President International Development Corp. Representative: Chiou-Ru Shih	<b>Director of :</b> SyNergy ScienTech Corp., Grand Bills Finance Corp., CDIB & Partners Investment Holding Corp., President Life Sciences Cayman Co., Ltd., Kunshan SYNergy ScienTech Co., Ltd., Androscience Corp. <b>Vice President of :</b> President International Development Corp.
National Development Fund, Executive Yuan	<b>Director of :</b> Genovate Biotechnology Co., Ltd., Taiwan Biotech Co., Ltd., Taiwan Flower Biotechnology Co., Ltd., United Biomedical Inc. (Asia), Adimmune Corp., TaiGen Biopharmaceuticals Holdings Ltd., PharmaEssentia Corp., PharmaEngine Inc., TaiAn Technologies Corp., TaiMed Biologics Inc., EirGenix Inc., MetaTech(AP) Inc., Wellell Inc., Point Robotics Holding Limited., Locus Cell Co., Ltd., Intech Biopharm Ltd., Taiwan Bio-Manufacturing Corp.
National Development Fund, Executive Yuan Representative: Ming-Chuan Hsieh	<b>Independent Director of :</b> Uni Pharma Co., Ltd., PharmaEssentia Corp.
Taiwan Sugar Corp.	Taiwan Sugar Corp. <b>Director of :</b> TaiGen Biopharmaceuticals Holdings Ltd., United Biomedical Inc. (Asia), Haleon Company
Taiwan Sugar Corp. Representative: Ling Ming Sun	<b>CEO of:</b> Biotechnology Division, Taiwan Sugar Corp. <b>Director of :</b> Haleon Company
Lewis Lee	<b>Independent Director of :</b> Brogent Technologies Inc., All Ring Tech Co., Ltd., Poya International Co., Ltd. Xiamen JinYuan President Securities Corp. Limited.
Wen-Chang Chang	<b>Director of :</b> Taipei Medical University <b>Independent Director of :</b> Taiwan Aulisa Medical Devices Technologies, Inc., Pharmosa Biopharm Inc. <b>Remuneration Committee member of :</b> Universal Cement Corp.
Li-Tzong Chen	<b>Consultant:</b> Academab Biomedical Inc.
Lai-Shou Su	<b>Director of:</b> Chuang Yi Biotech Co. Ltd., Top Pharma. Medicalware Co., Ltd., <b>Independent Director of:</b> Synmosa Biopharma Corp.